Russell Investments Group Ltd. lowered its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 3.8% during the second quarter, Holdings Channel reports. The institutional investor owned 442,680 shares of the biopharmaceutical company’s stock after selling 17,568 shares during the period. Russell Investments Group Ltd.’s holdings in Emergent Biosolutions were worth $15,010,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Emergent Biosolutions during the fourth quarter valued at $12,364,000. Aberdeen Asset Management PLC UK boosted its position in shares of Emergent Biosolutions by 29.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 1,618,576 shares of the biopharmaceutical company’s stock valued at $47,003,000 after buying an additional 369,908 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after buying an additional 238,194 shares in the last quarter. State Street Corp boosted its position in shares of Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after buying an additional 213,500 shares in the last quarter. Finally, Snyder Capital Management L P boosted its position in shares of Emergent Biosolutions by 17.8% in the first quarter. Snyder Capital Management L P now owns 1,134,332 shares of the biopharmaceutical company’s stock valued at $32,941,000 after buying an additional 171,636 shares in the last quarter. Institutional investors own 85.48% of the company’s stock.
Shares of Emergent Biosolutions, Inc. (NYSE EBS) traded down 2.21% on Thursday, reaching $34.45. The company had a trading volume of 121,454 shares. The company’s 50-day moving average price is $34.82 and its 200 day moving average price is $31.45. Emergent Biosolutions, Inc. has a 52 week low of $24.47 and a 52 week high of $36.95. The firm has a market capitalization of $1.42 billion, a P/E ratio of 21.94 and a beta of 1.22.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The company had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. During the same period in the previous year, the business posted ($0.05) earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. On average, analysts expect that Emergent Biosolutions, Inc. will post $1.55 EPS for the current year.
EBS has been the subject of several recent research reports. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Emergent Biosolutions presently has a consensus rating of “Hold” and an average price target of $44.00.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $36.50, for a total transaction of $912,500.00. Following the completion of the sale, the chairman now directly owns 1,630,216 shares of the company’s stock, valued at approximately $59,502,884. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.50% of the stock is currently owned by company insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.